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Smeasurements to follow-up, there was no signiﬁcant improvement in CFR immedi-
ately post TAVI (mean % DCFR pre TAVI to immediately post TAVI 8.6%, 95% CI
-23.0 – 40.3%, p¼0.41).
Conclusions: TAVI does improve coronary ﬂow dynamics as measured by CFR. This
improvement does not occur immediately, but requires a period of time post-TAVI to
manifest. The improvement in coronary ﬂow reserve may represent a mechanism by
which both symptoms and prognosis improve following TAVI.
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Background: Vascular complications remain to be the most prevalent adverse event
associated with transfemoral TAVI and related to increased morbidity and mortality.
Percutaneous implantation of stent grafts in the management of access-site related
vascular complications is not widely studied.
Methods: Among 379 patients who underwent TAVI from November 2007 to
December 2011 for severe aortic stenosis, transfermoral access was performed in 314
patients. 10 cases received surgical closure and consequently pure percutaneous
transfemoral TAVI was performed in 304 patients. We described the clinical outcomes
of this patient cohort who developed access-site related vascular complications and
were subsequently managed by percutaneous implantation of stent grafts. We also
compared their baseline clinical and procedural characteristics, as well as in-hospital
outcomes with those without vascular complications.
Results: Access site-related vascular complications occurred in 68 (22%) patients. 8
patients were managed surgically and 18 by manual compression. The remaining 42
patients with access site-related complications were managed by percutaneous means,
in which 29 were treated solely by implantation of stent grafts. Overall, stent graft
implantation was successful in all cases. The rate of VARC-deﬁned endpoints was
similar between patients managed by stent graft implantation and those free of
vascular complications. After a median follow-up of 19.2months, 9 patients under-
went Duplex ultrasonography of the intervened limb and the remaining patients
underwent clinical assessment. Duplex ultrasonography revealed no evidence of
obstructive ﬂow. Moreover, no patient experienced lower limb ischemic symptoms
during follow-up.
Conclusions: Access-site related vascular complications in transfemoral TAVI can be
managed by implantation of stent grafts with an encouraging technical success rate
and safety proﬁle. The clinical outcomes in these patients are similar to those who
have undergone transfemoral TAVI without vascular complications. However, more
dedicated imaging and larger clinical trials are needed to deﬁne the applicability of
stent grafts in the treatment of vascular complications in TAVI.
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Background: Post-procedural PVL  2 has been shown to be associated with worse
mid-term outcomes after TAVI. Valve calciﬁcation and optimal valve sizing may play
an important role in this setting. This study sought to identify predictive factors of
post-procedural paravalvular leak (PVL) 2 after transcatheter aortic valve implan-
tation (TAVI) with the Edwards valve.
Methods: A total of 176 Edwards TAVI patients (aged 83.47.4 years, Logistic
EuroSCORE 18.812.0, transfemoral 54.5%) who had preprocedural multislice
computed tomography (MSCT) were studied. In order to assess the role of valve
calciﬁcation, a new Valve Calciﬁcation Index (VCI) was deﬁned using MSCT as
aortic root calciﬁcation volume / aortic annulus area. Optimal valve sizing was deﬁned
as the valve diameter / calculated annulus average diameter (CAAD) by MSCT.
Results: After post dilatation, performed in 16.7% of cases, a PVL  2 was
observed in only 12.5% of cases. The 1-year estimated survival of both PVL < 2
and PVL  2 groups were 95.32.1% vs 79.010.8% (log-rank p¼0.02),
respectively. Only the VCI, odds ratio [OR] 2.11, 95% conﬁdence interval [CI] 1.27
to 3.51, p<0.01) and the valve diameter / CAAD (OR 0.57, 95% CI 0.38 to 0.87,
p¼0.01), were identiﬁed as independent predictors of post-procedural PVL  2. A
score predicting post-procedural PVL  2 (PVL score) was determined by assigning
one point when the Valve / CAAD ratio was < 1.05 and one point when VCI was >
2.05, and summing all points accrued. Area under receiver-operator characteristic
curves of PVL score were 0.70 (95% CI 0.58 to 0.82, p<0.01). The incidence of
PVL  2 in patients with a PVL score of 0 was 5.5%, 1 was 16.7% and 2 was
38.5%, respectively.B224 JACC Vol 62/18/Suppl B j October 27–NovemberConclusions: The only predictors of PVL  2 after Edwards valve implantation are
the valve diameter / CAAD and VCI. The use of these two simple parameters, could
become an excellent tool to predict the risk of PVL.
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment option for high-risk patients with severe aortic stenosis. The
second generation transapical JenaValve with its unique ﬁxation system enabling
anatomically correct positioning received CE-mark in September 2011. This registry
was designed to evaluate long-term safety and efﬁcacy of the transapical JenaValve
TAVI system in high-risk patients in a real world setting.
Methods: The registry will enroll a total of 180 patients undergoing TAVI with the
transapical JenaValve system and will follow them for a period of ﬁve years.
Endpoints are deﬁned according to Valve Academic Research Consortium (VARC)
with the primary endpoint 30-day mortality and secondary endpoints safety, device
success, effectiveness and quality of life at up to 5 years.
Results: In the JUPITER-Registry, so far 56% of the patients, i.e. a total of 101
patients underwent elective TAVI at 11 European centres. Currently procedural
outcome is available on 88 patients (mean age 80.86.1 years; EuroSCORE
24.913.5%), of whom 84 underwent successful TAVI using the JenaValve resulting
in a procedural success of 95.5%. 2 patients were converted to surgical AVR, 2
patients to a valve-in-valve procedure. 30 day all-cause mortality was 14.9%,
cardiovascular mortality 4.7%. TAVI resulted in favourable reduction of mean
transvalvular gradients (40.414.4mmHg vs. 8.14.9mmHg, p< 0.0001). No or trace
paravalvular leakage (PVL) was present in 80.2% of patients, mild PVL in 17.4% and
moderate PVL in 2.3%. None of the patients had severe post procedural aortic
regurgitation (> grade 2). Complete 30-day results according to VARC criteria of 75
% of the patients, i.e. 135 patients will be presented at the conference.
Conclusions: Interim results of the JUPITER registry demonstrate that TAVI using
the JenaValve system results in high procedural success, excellent hemodynamics and
low incidence of paravalvular leakage. Thirty-day mortality in this very high-risk
group is slightly high in this interim analysis, but ﬁnal results remain to be seen when
data for all 180 patients are available.
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Background: Starting a TAVI program mandates to keep efﬁcacy and safety
competitive in relation to conventional surgery, while implementing a procedure that
requires new skills and close cooperation between different specialties. In this
complex scenario, monitoring the overall and individual performance is essential. The
aim of the present study was to apply control charts (CUSUM curves) to monitor the
performance of the TAVI team and to enhance the quality control for that procedure.
Methods: The ﬁrst 90 patients undergoing TAVI at our institution were prospectively
monitored, using risk-adjusted CUSUM curves. Predicted risks of failure for indi-
vidual patients were derived from the literature. The following endpoints were
considered: (1) Technical device success (TDS); (2) 30-days mortality (HM); (3) 30-
days freedom from adverse events (FAE).
Results: All patients received a Sapien valve via a transapical (43) or transfemoral
(47) approach. median age was 80.6 years, the median Euroscore and STS score were
24.1 and 9.82. The TDS and the HM CUSUM curves showed an initial cluster of 3
(TDS) and 2 (HM) failures in the ﬁrst 12 procedures, probably reﬂecting the traversing
of the learning curve. Consecutively we experienced a period of good performance
and the process came in control at operation number 29 (TDS) and 26 (HM). The FAE
curve behaved similarly, but a steep upward trend was observed starting from patient
38, and the boundary line was crossed at the 45th patient, indicating that the procedure
was going out of control. An internal audit identiﬁed as possible causes of failure an
inappropriate patients' selection and the lack of a dedicated "Post-procedural care"
team. The correction of these problems led to a downward shift of the CUSUM curve,1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
